COMP <GO>
HAE vs UNH // PIOTROSKI F-SCORE QUALITY
Haemonetics Corporation (NYSE) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: HAE 4
— UNH 8
■ METRIC PARITY
LAST: $120.14 (+0.41%) • MKT CAP: $5.44B
piotroski-score
7/9
LAST: $400.44 (-1.60%) • MKT CAP: $365.29B
piotroski-score
7/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HAE VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HAE | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 59.00% | 88.57% | -29.57 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.40% | 11.47% | -3.07 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 32.5x | 16.5x | +16.02 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 4.78% | 6.47% | -1.69 | UNH | /fcf-yield <GO> |
| Operating Margin | 11.70% | 4.82% | +6.88 | HAE | /operating-margins <GO> |
| Net Profit Margin | 0.00% | 3.14% | -3.14 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | -2.00% | 6.46% | -8.46 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.32% | -2.32 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.89 | 3.12 | +0.77 | HAE | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.11% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 63.0 | 57.4 | +5.60 | HAE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 0.33 | +0.67 | HAE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 17.7x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.44B | $365.29B | -$359.85B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HAE REV | UNH REV | HAE GROSS % | UNH GROSS % | HAE FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.33B | $447.57B | 59.0% | 88.7% | $260.4M | $16.07B |
| FY 2024 | $1.36B | $400.28B | 55.0% | 88.3% | $142.4M | $20.70B |
| FY 2023 | $1.31B | $371.62B | — | 89.6% | $122.8M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HAE // BETA 1.00
UNH // BETA 0.33